MichaelJBiunnoMD

Psychiatry • New Orleans, LA

Louisiana Research Associates

Join to view full profile

Dr. Biunno is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Biunno's full profile

Already have an account?

Office
2401 Westbend Pkwy
Ste 4030
New Orleans, LA 70114
Phone+1 504-363-7448

Fax+1 504-363-7421

Education & Training

Tulane UniversityResidency, Psychiatry, 1990 - 1993
Louisiana State University School of MedicineInternship, Transitional Year, 1989 - 1990
Rutgers New Jersey Medical SchoolClass of 1989

Certifications & Licensure

LA State Medical License 1990 - 2025
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Maintenance of Efficacy of Extended-Release Guanfacine HCl in Children and Adolescents With Attention-deficit/Hyperactivity Disorder (ADHD) Start of enrollment: 2010 May 11
Completed
Phase 3
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia Start of enrollment: 2011 Mar 01
Completed
Phase 3
Evaluation of the Efficacy and Safety of ADL5945 Once Daily for the Treatment of Opioid-induced Constipation in Adults Taking Opioid Therapy for Chronic Noncancer Pain Start of enrollment: 2011 Jan 19
Completed
Phase 2
Forced-dose Titration of SPD489 in Adults With Binge Eating Disorder Start of enrollment: 2011 May 10
Completed
Phase 2
Smoking Cessation Study In Healthy Adolescent Smokers Start of enrollment: 2011 Apr 01
Completed
Phase 4
Progress of Mild Alzheimer's Disease in Participants on Solanezumab Versus Placebo Start of enrollment: 2013 Jul 01
Terminated
Phase 3
Dasotraline SEP360-105 Pediatric PK/PD Study Start of enrollment: 2014 Jul 01
Completed
Phase 1
Safety and Efficacy Study of SHP465 in Children and Adolescents Aged 6-17 Years With Attention-Deficit Hyperactivity Disorder (ADHD) Start of enrollment: 2015 Jun 18
Completed
Phase 3
Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder Start of enrollment: 2015 Jul 27
Completed
Phase 3
Join now to see all